Promoting exogenous repair in multiple sclerosis: myelin regeneration.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
10
6
2022
Statut:
ppublish
Résumé
Despite the significant progress in the development of disease-modifying treatments for multiple sclerosis (MS), repair of existing damage is still poorly addressed. Current research focuses on stem cell-based therapies as a suitable alternative or complement to current drug therapies. Myelin damage is a hallmark of multiple sclerosis, and novel approaches leading to remyelination represent a promising tool to prevent neurodegeneration of the underlying axon. With increasing evidence of diminishing remyelination capacity of the MS brain with ageing and disease progression, exogenous cell transplantation is a promising therapeutic approach for restoration of oligodendrocyte precursor cell pool reserve and myelin regeneration. The present review summarizes recent developments of remyelinating therapies in multiple sclerosis, focusing on exogenous cell-based strategies and discussing related scientific, practical, and ethical concerns.
Identifiants
pubmed: 35674074
doi: 10.1097/WCO.0000000000001062
pii: 00019052-202206000-00010
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-318Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129:606–616.
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83:278–286.
Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430–1438.
Stys PK, Zamponi GW, Van Minnen J, et al. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012; 13:507–514.
Faissner S, Gold R. Progressive multiple sclerosis: latest therapeutic developments and future directions. Ther Adv Neurol Disord 2019; 12:1756286419878323.
Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129:3165–3172.
Chari DM. Remyelination in multiple sclerosis. Int Rev Neurobiol 2007; 79:589–620.
Duncan ID, Marik RL, Broman AT, et al. Thin myelin sheaths as the hallmark of remyelination persist over time and preserve axon function. Proc Natl Acad Sci USA 2017; 114:E9685–E9691.
Neely SA, Williamson JM, Klingseisen A, et al. New oligodendrocytes exhibit more abundant and accurate myelin regeneration than those that survive demyelination. Nat Neurosci 2022; 25:415–420.
Hagemeier K, Brück W, Kuhlmann T. Multiple sclerosis – remyelination failure as a cause of disease progression. Histol Histopatol 2012; 27:277–287.
Franklin RJM, Frisén J, Lyons DA. Revisiting remyelination: towards a consensus on the regeneration of CNS myelin. Semin Cell Dev Biol 2021; 116:3–9.
Sharrack B, Saccardi R, Alexander T, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant 2019; 55:283–306.
Li Z, Liu F, He X, et al. Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia. Int Immunopharmacol 2019; 67:268–280.
Butti E, Cusimano M, Bacigaluppi M, et al. Neurogenic and nonneurogenic functions of endogenous neural stem cells. Front Neurosci 2014; 0:92.
Kokaia Z, Martino G, Schwartz M, et al. Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci 2012; 15:1078–1087.
Chu K, Kim M, Jeong SW, et al. Human neural stem cells can migrate, differentiate, and integrate after intravenous transplantation in adult rats with transient forebrain ischemia. Neurosci Lett 2003; 343:129–133.
Pluchino S, Cossetti C. How stem cells speak with host immune cells in inflammatory brain diseases. Glia 2013; 61:1379–1401.
Lu P, Jones LL, Snyder EY, et al. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol 2003; 181:115–129.
Lanza C, Morando S, Voci A, et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 2009; 110:1674–1684.
Bai L, Lennon DP, Caplan AI, et al. Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models. Nat Neurosci 2012; 15:862–870.
Zhang J, Li Y, Chen J, et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005; 195:16–26.
Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106:1755–1761.
Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies. Int J Mol Sci 2020; 21:8662.
Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 2020; 143:3574–3588.
Smith JA, Nicaise AM, Ionescu R-B, et al. Stem cell therapies for progressive multiple sclerosis. Front Cell Dev Biol 2021; 9:1751.
Uccelli A, Laroni A, Ali R, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol 2021; 20:917–929.
Banks WA, Sharma P, Bullock KM, et al. Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation. Int J Mol Sci 2020; 21:4407.
Branscome H, Paul S, Yin D, et al. Use of stem cell extracellular vesicles as a ‘Holistic’ approach to CNS repair. Front Cell Dev Biol 2020; 8:455.
Jafarinia M, Alsahebfosoul F, Salehi H, et al. Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis. J Cell Physiol 2020; 235:8779–8790.
Vescovi AL, Gritti A, Galli R, et al. Isolation and intracerebral grafting of nontransformed multipotential embryonic human CNS stem cells. J Neurotrauma 1999; 16:689–693.
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861–872.
Laterza C, Merlini A, De Feo D, et al. iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF. Nat Commun 2013; 4:2597.
De Feo D, Merlini A, Brambilla E, et al. Neural precursor cell–secreted TGF-β2 redirects inflammatory monocyte-derived cells in CNS autoimmunity. J Clin Invest 2017; 127:3937–3953.
Piaton G, Aigrot MS, Williams A, et al. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain 2011; 134:1156–1167.
Starossom SC, Campo Garcia J, Woelfle T, et al. Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. Nat Commun 2019; 10:217.
Neyrinck K, García-León JA. Single transcription factor-based differentiation allowing fast and efficient oligodendrocyte generation via SOX10 overexpression. Methods Mol Biol 2021; 2352:149–170.
Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. N Engl J Med 2020; 382:1926–1932.
Ehrlich M, Mozafari S, Glatza M, et al. Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors. Proc Natl Acad Sci USA 2017; 114:E2243–E2252.
Mozafari S, Starost L, Manot-Saillet B, et al. Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo. Sci Adv 2020; 6:1–15.
Mozafari S, Laterza C, Roussel D, et al. Skin-derived neural precursors competitively generate functional myelin in adult demyelinated mice. J Clin Invest 2015; 125:3642–3656.
Mozafari S, Baron-Van Evercooren A. Human stem cell-derived oligodendrocytes: From humanized animal models to cell therapy in myelin diseases. Semin Cell Dev Biol 2021; 116:53–61.
Yong KSM, Her Z, Chen Q. Humanized mice as unique tools for human-specific studies. Arch Immunol Ther Exp 2018; 66:245–266.
Aboody K, Capela A, Niazi N, et al. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron 2011; 70:597–613.
Yamanaka S. Pluripotent stem cell-based cell therapy – promise and challenges. Stem Cell 2020; 27:523–531.
Gore A, Li Z, Fung H-L, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471:63–67.
Fernandez-Muñoz B, Garcia-Delgado AB, Arribas-Arribas B, et al. Human neural stem cells for cell-based medicinal products. Cells 2021; 10:2377.
Pluchino S, Quattrini A, Brambilla E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003; 422:688–694.
Einstein O, Karussis D, Grigoriadis N, et al. Intraventricular transplantation of neural precursor cell spheres attenuates acute experimental allergic encephalomyelitis. Mol Cell Neurosci 2003; 24:1074–1082.
Pluchino S, Zanotti L, Rossi B, et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005; 436:266–271.
Pluchino S, Gritti A, Blezer E, et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in nonhuman primates. Ann Neurol 2009; 66:343–354.
Harris VK, Stark J, Vyshkina T, et al. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine 2018; 29:23–30.
Harris VK, Stark JW, Yang S, et al. Mesenchymal stem cell-derived neural progenitors in progressive MS. Neurol - Neuroimmunol Neuroinflammation 2021; 8:e928.
Mansilla MJ, Presas-Rodríguez S, Teniente-Serra A, et al. Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. Cell Mol Immunol 2021; 18:1353–1374.
Pluchino S, Smith JA, Peruzzotti-Jametti L. Promises and limitations of neural stem cell therapies for progressive multiple sclerosis. Trends Mol Med 2020; 26:898–912.